Login to Your Account

In The Clinic NEWS

Threshold Pharmaceuticals Inc. said it would discontinue development of EGFR-targeted tarloxotinib after the oncology candidate fell short of its expectations in dual phase II proof-of-concept trials.

Investors in Aurinia Pharmaceuticals Inc. breathed a sigh of relief, and moved shares higher, after learning that both study doses in the phase IIb AURA-LV study of lupus nephritis candidate, voclosporin, met 24-week pre-specified secondary endpoints compared to control.

An elevated placebo response matching the efficacy of experimental schizophrenia drug ITI-007 in a phase III trial sent shares of its developer, Intra-Cellular Therapies Inc., down 63.6 percent Thursday.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: